A checklist is presented to assist with the evaluation of a controlled trial in migraine prophylaxis. The following points are discussed briefly: aim of the study, design of the study, efficacy parameters, and presentation of results and statistics. Choice among drugs for migraine prophylaxis is described taking into account: clinical efficacy, scientific proof for efficacy, and contraindications.
International Headache Society Committee on Clinical Trials in Migraine.Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia1991; 11: 1–12
4.
JohnsonES, Tfelt-HansenP.Fundamentals of clinical pharmacology. In: OlesenJ, Tfelt-HansenP, WelchKMA editors. The headaches.New York: Raven Press, 1993: 153–7
5.
Migraine-Nimodipine European Study Group (MINES).European multicenter trial of nimodipine in the prophylaxis of classical migraine (migraine with aura). Headache1989; 29: 639–42
6.
OlesenJ, KrabbeAE, Tfelt-HansenP.Methodological aspects of prophylactic drug trials in migraine. Cephalalgia1981; 1: 127–41
7.
Tfelt-HansenP, StandnesB, KangasneimiP, HakkarainenH, OlesenJ.Timolol vs propranolol vs placebo in common migraine. Acta Neurol Scand1984; 69: 1–8
8.
KangasneimiP, HedmanC.Metoprolol and propranolol in the prophylactic treatment of common and classical migraine: a double-blind study. Cephalalgia1984; 4: 91–6
9.
LouisP, SchonenJ, HedmanC.Metoprolol v. Clonidine in the prophylactic treatment of migraine. Cephalalgia1985; 5: 159–65
